Welcome to our dedicated page for Apyx Medical SEC filings (Ticker: APYX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Apyx Medical's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Apyx Medical's regulatory disclosures and financial reporting.
Apyx Medical Corp director Minnie Baylor-Henry received a compensatory stock option grant for 50,000 shares of common stock on June 11, 2026. The option has an exercise price of $4.65 per share and expires on June 11, 2036.
The option vests ratably over a twelve-month period and becomes fully vested and exercisable on the first anniversary of the grant date. Following this award, the filing shows 50,000 derivative securities (options) held directly.
Apyx Medical Corp director Lawrence Waldman received a grant of stock options as compensation. He was awarded options to buy 50,000 shares of common stock at an exercise price of $4.6500 per share, expiring on June 11, 2036. According to the terms, the option vests ratably over a 12‑month period and becomes fully vested and fully exercisable on the first anniversary of the grant date. Following this award, Waldman holds 50,000 stock options directly under this grant.
Apyx Medical Corp reported that Chief Financial Officer Matthew C. Hill received a grant of stock options as part of his compensation. The award covers 132,066 options to buy common stock at an exercise price of $4.65 per share, expiring on June 11, 2036. According to the disclosure, these options vest ratably over a thirty-six month period and become fully vested and exercisable on the third anniversary of the grant date. Following this grant, Hill holds 132,066 stock options directly, and the filing shows no open-market purchases or sales.
Apyx Medical Corp reported that Sr. V.P. of Operations Moshe Citronowicz received a grant of stock options. The award covers 63,392 options to buy common stock at an exercise price of $4.65 per share, expiring on June 11, 2036.
According to the disclosure, these options were granted at no cost and will vest ratably over 36 months, becoming fully vested and exercisable on the third anniversary of the grant date. Following this grant, the filing shows beneficial ownership of 63,392 derivative securities directly held as options.
Apyx Medical Corporation filed an 8-K to highlight new clinical data supporting its minimally invasive technologies for treating cellulite and skin laxity. The study, published in Aesthetic Surgery Journal Open Forum, evaluated a single-session combination treatment using Avéli for targeted subcision and Renuvion for controlled helium plasma radiofrequency tightening.
The prospective investigator-initiated study treated 22 patients and reported progressive improvement over time, with visible reductions in cellulite and, in a subset of patients, increased collagen and elastin levels through 180 days after treatment. These results add to the company’s evidence base for its Renuvion and AYON body contouring platforms, which are already backed by more than 90 clinical documents.
Apyx Medical Corporation filed an 8-K to highlight a new retrospective, investigator-initiated clinical publication evaluating its Renuvion® technology used with liposuction. The 113-patient study in Plastic and Reconstructive Surgery – Global Open found that adding helium plasma radiofrequency (Renuvion) after liposuction was associated with higher patient-reported satisfaction with abdominal appearance and excess skin, lower abdominoplasty and surgical revision rates, and complication rates comparable to conventional power-assisted liposuction alone.
The company notes this study adds to a body of more than 90 clinical documents supporting Renuvion and J-Plasma®. It also reiterates that its AYON Body Contouring System™ is an FDA-cleared, surgeon-designed platform integrating fat removal, contouring and Renuvion-based tissue contraction, and that an additional 510(k) for AYON label expansion to include power liposuction was filed in October 2025.
Apyx Medical Corporation reported that it has received expanded FDA 510(k) clearance for its AYON Body Contouring System, adding a power liposuction capability. This advanced liposuction uses a reciprocating cannula designed to improve fat removal efficiency and reduce surgeon effort and operating room time.
The company plans a limited commercial launch of the new power liposuction function to work closely with early adopters, refine training, and optimize utilization before scaling broader commercialization. AYON is described as an all-in-one, surgeon-designed body contouring platform that integrates fat removal, contouring, tissue contraction, and electrosurgical capabilities.
Apyx Medical Corporation reported first-quarter 2026 net sales of $12.5 million, up 32.4% from $9.4 million a year earlier, driven mainly by its Surgical Aesthetics segment and the AYON body contouring system. Gross profit rose to $7.9 million, lifting gross margin to 63.5% from 60.1% as higher-margin surgical aesthetics products made up a larger share of revenue.
The company reduced its net loss attributable to stockholders to $2.1 million, or $0.05 per share, compared with a $4.2 million loss, or $0.10 per share, in the prior-year quarter. Operating cash outflow was modest at $0.6 million, and cash and cash equivalents were $31.1 million at March 31, 2026. Apyx carries a $37.5 million term loan under its Perceptive Credit Agreement at a 12.0% interest rate and remains subject to revenue and operating expense covenants.
Management highlights strong growth in Surgical Aesthetics, with segment sales up 36.1% to $10.7 million, and notes that international revenue increased to 35.1% of total sales. At the same time, the company continues to incur recurring net losses and expects near-term losses to continue, indicating an ongoing need to balance growth investments, debt obligations and potential future financing.
Apyx Medical Corporation reported strong first quarter 2026 growth with higher revenue and narrower losses. Sales rose to $12.5 million from $9.4 million, led by Surgical Aesthetics revenue of $10.7 million, up 36.1% year over year, and OEM revenue of $1.8 million, up 13.8%.
Gross profit increased to $7.9 million with gross margin improving to 63.5%. Net loss attributable to stockholders improved to $2.1 million, or $0.05 per share, compared with a $4.2 million loss, or $0.10 per share, a year earlier. Adjusted EBITDA loss narrowed to $0.3 million from $2.4 million.
The company ended March 31, 2026 with $31.1 million in cash and cash equivalents and raised full‑year 2026 total revenue guidance to a range of $59.0 million to $60.0 million, citing strong uptake of the AYON Body Contouring System and better‑than‑expected international demand.
Apyx Medical Corp Senior Vice President Moshe Citronowicz exercised a stock option to acquire 37,000 shares of common stock at $1.80 per share under the company’s 2015 Share Incentive Plan. Following the transaction, he directly owns 493,504 shares of Apyx Medical common stock, indicating a routine compensation-related increase in his equity stake.